Skip to content

Released May 6, 2021, after the close

10-Q filed May 7, 2021, 37 days after period end · 0001564590-21-025155

Q1 2021 · 10-Q
Revenue$14.66M+105.0% vs Q1 2020+77.1% vs Q4 2020
Net Income-$30.36MN/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.66N/M vs Q1 2020N/M vs Q4 2020
Operating Income-$19,009,000N/M
Operating Cash Flow-$30,430,000N/M
Margins · derived
Operating margin-129.7%+138.5 pt vs Q1 2020
Net margin-207.1%+66.9 pt vs Q1 2020

What the release said

The release

Same quarter

MetricQ1 2021Q1 2020Q1 2019Q1 2018
Revenue$14.66M$7.15M$8.63M$5.79M
Net Income-$30.36M-$19.60M-$14.25M-$12.05M
EPS Diluted-$0.66-$0.84-$0.62-$25.76

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR